


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:04Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405970" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405970</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" id="eji70049" xml:lang="en" article-type="other" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">EJI</journal-id><journal-title-group><journal-title>European Journal of Immunology</journal-title></journal-title-group><issn pub-type="ppub">0014-2980</issn><issn pub-type="epub">1521-4141</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405970</article-id><article-id pub-id-type="pmcid-ver">PMC12405970.1</article-id><article-id pub-id-type="pmcaid">12405970</article-id><article-id pub-id-type="pmcaiid">12405970</article-id><article-id pub-id-type="pmid">40899093</article-id><article-id pub-id-type="doi">10.1002/eji.70049</article-id><article-id pub-id-type="publisher-id">EJI70049</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Notes and Insights</subject></subj-group><subj-group subj-group-type="heading"><subject>Notes and Insights</subject></subj-group></article-categories><title-group><article-title>Perturbances in Both Circulating B and CD4<sup>+</sup> T Cells Discriminate Multiple Sclerosis from Other Central Nervous System Autoimmune Diseases</article-title></title-group><contrib-group><contrib id="eji70049-cr-0001" contrib-type="author"><name name-style="western"><surname>Bogers</surname><given-names initials="L">Laurens</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8490-3076</contrib-id><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0002" contrib-type="author"><name name-style="western"><surname>Rip</surname><given-names initials="J">Jasper</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5780-9271</contrib-id><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0003" contrib-type="author"><name name-style="western"><surname>Franken</surname><given-names initials="SC">Suzanne C.</given-names></name><xref rid="eji70049-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="eji70049-cr-0004" contrib-type="author"><name name-style="western"><surname>Kuiper</surname><given-names initials="KL">Kirsten L.</given-names></name><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0005" contrib-type="author"><name name-style="western"><surname>Marques</surname><given-names initials="AM">Ana M.</given-names></name><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0006" contrib-type="author"><name name-style="western"><surname>Wierenga&#8208;Wolf</surname><given-names initials="AF">Annet F.</given-names></name><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0007" contrib-type="author"><name name-style="western"><surname>Melief</surname><given-names initials="MJ">Marie&#8208;Jos&#233;</given-names></name><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="eji70049-cr-0008" contrib-type="author"><name name-style="western"><surname>Corsten</surname><given-names initials="CEA">Cato E. A.</given-names></name><xref rid="eji70049-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="eji70049-cr-0009" contrib-type="author"><name name-style="western"><surname>Kranenbarg</surname><given-names initials="RAMK">Romy A. M. Klein</given-names></name><xref rid="eji70049-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="eji70049-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="eji70049-cr-0010" contrib-type="author"><name name-style="western"><surname>de Beukelaar</surname><given-names initials="J">Janet</given-names></name><xref rid="eji70049-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="eji70049-cr-0011" contrib-type="author"><name name-style="western"><surname>Smets</surname><given-names initials="I">Ide</given-names></name><xref rid="eji70049-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="eji70049-cr-0012" contrib-type="author"><name name-style="western"><surname>Wokke</surname><given-names initials="BH">Beatrijs H.</given-names></name><xref rid="eji70049-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="eji70049-cr-0013" contrib-type="author"><name name-style="western"><surname>Titulaer</surname><given-names initials="MJ">Maarten J.</given-names></name><xref rid="eji70049-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="eji70049-cr-0014" contrib-type="author"><name name-style="western"><surname>Smolders</surname><given-names initials="J">Joost</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9766-8661</contrib-id><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="eji70049-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="eji70049-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="eji70049-cr-0015" contrib-type="author" corresp="yes"><name name-style="western"><surname>van Luijn</surname><given-names initials="MM">Marvin M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1283-1018</contrib-id><xref rid="eji70049-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>m.vanluijn@erasmusmc.nl</email></address></contrib></contrib-group><aff id="eji70049-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Immunology</named-content>
<named-content content-type="organisation-division">MS Center ErasMS</named-content>
<institution>Erasmus University Medical Center</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="eji70049-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Erasmus University Medical Center</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="eji70049-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<named-content content-type="organisation-division">MS Center ErasMS</named-content>
<institution>Erasmus University Medical Center</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="eji70049-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Albert Schweitzer Hospital</institution>
<city>Dordrecht</city>
<country country="NL">The Netherlands</country>
</aff><aff id="eji70049-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Neuroimmunology Research Group</named-content>
<institution>Netherlands Institute for Neuroscience</institution>
<city>Amsterdam</city>
<country country="NL">The Netherlands</country>
</aff><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>55</volume><issue seq="10">9</issue><issue-id pub-id-type="pmc-issue-id">496084</issue-id><issue-id pub-id-type="doi">10.1002/eji.v55.9</issue-id><elocation-id>e70049</elocation-id><history><date date-type="rev-recd"><day>18</day><month>8</month><year>2025</year></date><date date-type="received"><day>23</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">European Journal of Immunology</italic> published by Wiley&#8208;VCH GmbH.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="EJI-55-e70049.pdf"/><self-uri content-type="pdf" xlink:href="file:EJI-55-e70049.pdf"/><abstract id="eji70049-abs-0001" abstract-type="graphical"><p>Using spectral flow cytometry, we analyzed circulating lymphocyte subsets in treatment&#8208;naive individuals with multiple sclerosis (MS) and other central nervous system autoimmune diseases (CNS AIDs). Elevated B&#8208;cell and CD4<sup>+</sup> T&#8208;cell frequencies were a disease&#8208;specific feature of MS, while reduced T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> B&#8208;cell levels were associated with progressive disease.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="EJI-55-e70049-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="eji70049-kwd-0001">anti&#8208;AQP4 NMOSD</kwd><kwd id="eji70049-kwd-0002">autoimmune encephalitis</kwd><kwd id="eji70049-kwd-0003">disease progression</kwd><kwd id="eji70049-kwd-0004">disease specificity</kwd><kwd id="eji70049-kwd-0005">MOGAD</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Stichting MS Research</institution><institution-id institution-id-type="doi">10.13039/501100003000</institution-id></institution-wrap></funding-source><award-id>19&#8208;1057 MS</award-id><award-id>20&#8208;490f MS</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Stichting de Merel</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Erasmus MC Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Stichting Dioraphte</institution><institution-id institution-id-type="doi">10.13039/501100010573</institution-id></institution-wrap></funding-source><award-id>2001 0403</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="0"/><page-count count="4"/><word-count count="1963"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:03.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="eji70049-cit-0001"><string-name name-style="western"><given-names>L.</given-names><surname>Bogers</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rip</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Franken</surname></string-name>, et al. &#8220;<article-title>Perturbances in Both Circulating B and CD4<sup>+</sup> T Cells Discriminate Multiple Sclerosis from Other Central Nervous System Autoimmune Diseases</article-title>.&#8221; <source>European Journal of Immunology</source><volume>55</volume>, no. <issue>9</issue> (<year>2025</year>): <volume>55</volume>, <elocation-id>e70049</elocation-id>. <pub-id pub-id-type="doi">10.1002/eji.70049</pub-id><pub-id pub-id-type="pmid">40899093</pub-id><pub-id pub-id-type="pmcid">PMC12405970</pub-id></mixed-citation>
</p><fn-group><fn id="eji70049-note-0001"><p>Laurens Bogers and Jasper Rip Shared authorship.</p></fn></fn-group></notes></front><body><p>B cells play a central role in many central nervous system autoimmune diseases (CNS AIDs), including multiple sclerosis (MS) [<xref rid="eji70049-bib-0001" ref-type="bibr">1</xref>]. For the development of MS, B cells are likely misinformed by CD4<sup>+</sup> T helper cells both outside and inside the CNS [<xref rid="eji70049-bib-0002" ref-type="bibr">2</xref>]. As a result, memory B cells enter the CNS and subsequently differentiate into antibody&#8208;secreting cells (ASCs) [<xref rid="eji70049-bib-0002" ref-type="bibr">2</xref>, <xref rid="eji70049-bib-0003" ref-type="bibr">3</xref>, <xref rid="eji70049-bib-0004" ref-type="bibr">4</xref>]. Locally produced antibodies likely contribute to MS pathology, although a specific target antigen has not been identified [<xref rid="eji70049-bib-0005" ref-type="bibr">5</xref>]. Other CNS AIDs such as autoimmune encephalitis (AE) and rare demyelinating diseases (RDD), including AQP4&#8208;IgG<sup>+</sup> neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody&#8208;associated disease (MOGAD), are characterized by specific circulating CNS&#8208;directed antibodies [<xref rid="eji70049-bib-0006" ref-type="bibr">6</xref>, <xref rid="eji70049-bib-0007" ref-type="bibr">7</xref>]. For such diseases, intrathecal antibody production is less common, but highly variable, and thus cannot be seen as a specific immunological hallmark of MS [<xref rid="eji70049-bib-0001" ref-type="bibr">1</xref>]. Besides for differences in antibody specificity and compartmentalization, we do not know if the distribution and features of B cells amongst other circulating lymphocytes could be useful to discriminate MS from other CNS AIDs. A major hurdle is that steroid treatment often confounds the interpretation of such disease&#8208;specific cellular alterations.</p><p>To address this, we performed spectral flow cytometry on blood samples from healthy individuals (young/old) and people with MS (relapsing/progressive), AE (anti&#8208;LGI1/&#8208;IgLON5/&#8208;GAD65), or RDD (anti&#8208;AQP4 NMOSD/MOGAD) who did not receive any immunomodulatory treatment at the time of sampling (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1A</xref>).</p><fig position="float" fig-type="FIGURE" id="eji70049-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Increased B&#8208; and CD4<sup>+</sup> T&#8208;cell frequencies in blood of people with MS. (A) Thawed blood samples from healthy controls (young/old; <italic toggle="yes">n</italic>&#160;=&#160;12) and treatment&#8208;naive individuals with MS (relapsing/progressive; <italic toggle="yes">n</italic>&#160;=&#160;12), AE (anti&#8208;LGI1/&#8208;IgLON5/&#8208;GAD65; <italic toggle="yes">n</italic>&#160;=&#160;10) or RDD (anti&#8208;AQP4 NMOSD/MOGAD; <italic toggle="yes">n</italic>&#160;=&#160;6) were analyzed using ex vivo spectral flow cytometry. (B) Gating strategy of B&#8208;, T&#8208;, and NK&#8208;cell subsets. (C) B&#8208;, T&#8208;, and NK&#8208;cell frequencies within viable lymphocytes. (D) CD4<sup>+</sup> and CD8<sup>+</sup> frequencies within total T cells. (E) CD4<sup>+</sup>/CD8<sup>+</sup> T&#8208;cell ratios. (F) Transitional, naive mature, memory, and double negative (DN; CD27<sup>&#8722;</sup>IgD<sup>&#8722;</sup>) frequencies within total B cells. All data are presented as mean &#177;SEM and analyzed using Kruskal&#8208;Wallis and Dunn's post hoc tests. Outliers were identified and excluded using Grubbs&#8217; test. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ***<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001.</p></caption><graphic position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="EJI-55-e70049-g001.jpg"/></fig><p>First, we evaluated differences in major lymphocyte subsets within thawed blood samples (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1B</xref>). While NK&#8208;cell frequencies were similar between groups, T&#8208;cell frequencies were reduced in RDD, and B&#8208;cell frequencies were notably increased in both MS and RDD (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1C</xref>). CD4<sup>+</sup> T cells were significantly elevated, while CD8<sup>+</sup> T cells were significantly diminished in MS, as reflected by frequencies (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1D</xref>) and CD4<sup>+</sup>/CD8<sup>+</sup> T&#8208;cell ratios (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1E</xref>). The observed effects were not sex&#8208;dependent (Figure <xref rid="eji70049-supinfo-0001" ref-type="">S1A,B</xref>). No major differences were observed in other B&#8208;, T&#8208;, and NK&#8208;cell subpopulations (Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1F</xref>; Figure <xref rid="eji70049-supinfo-0001" ref-type="">S1C&#8211;G</xref>). The selective enrichment of both circulating B cells and CD4<sup>+</sup> T cells in people with MS points to disease&#8208;specific changes in lymphocyte fractions and thereby could reflect a distinct underlying mechanism per antibody&#8208;associated CNS AID group, which requires validation and further investigation in the near future.</p><p>To better understand the implications of elevated B&#8208; and CD4<sup>+</sup> T&#8208;cell frequencies in MS, we further analyzed whether T&#8208;bet and CXCR3, as markers of CD4<sup>+</sup> T&#8208;cell interaction and CNS&#8208;homing, are differentially expressed by B cells in the MS versus the RDD and AE groups. First, we observed no sex&#8208;related effects on T&#8208;bet and CXCR3 expression (Figure <xref rid="eji70049-supinfo-0001" ref-type="">S2A,B</xref>). No major differences were found when comparing disease groups in total B cells and memory populations, although we did observe a trend toward lower T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> B&#8208;cell frequencies in MS and RDD (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2A,B</xref>; Figure <xref rid="eji70049-supinfo-0001" ref-type="">S2C,D</xref>). Within the MS group, the proportions of both T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> B cells were markedly reduced in people with advanced progressive versus early relapsing disease (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2A,B</xref>; Figure <xref rid="eji70049-supinfo-0001" ref-type="">S2C,D</xref>), a pattern not observed for CD4<sup>+</sup> memory T cells (Figure <xref rid="eji70049-supinfo-0001" ref-type="">S3A,B</xref>). No reduction was found when comparing aged versus young healthy individuals (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2A,B</xref>; Figure <xref rid="eji70049-supinfo-0001" ref-type="">S2C,D</xref>), suggesting that age is not a determining factor for these lower proportions. Additionally, circulating memory B cells from the progressive MS subgroup showed decreased differentiation into CD27<sup>high</sup>CD38<sup>high</sup> ASCs under in vitro conditions that mimic CD4<sup>+</sup> T&#8208;cell help, which was IFN&#8208;&#947;&#8208;dependent (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2C</xref>). CXCR3 expression on in vitro&#8208;induced ASCs positively correlated with that on ex vivo memory B cells (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2D</xref>) and was lower in the advanced progressive than the early relapsing subgroup (Figure <xref rid="eji70049-supinfo-0001" ref-type="">S4A,B</xref>). We validated our findings by using another MS cohort, in which ex vivo ASCs could be measured in fresh blood samples and showed a significant reduction in people with progressive versus relapsing disease (Figure&#160;<xref rid="eji70049-fig-0002" ref-type="fig">2E</xref>). These data may suggest that CXCR3<sup>+</sup> memory B cells&#8212;which drive hyperreactive B&#8211;T cell interactions in MS<sup>2</sup> and show a high ASC differentiation capacity [<xref rid="eji70049-bib-0008" ref-type="bibr">8</xref>]&#8212;could redistribute to the CNS of individuals with longstanding progressive MS [<xref rid="eji70049-bib-0003" ref-type="bibr">3</xref>, <xref rid="eji70049-bib-0004" ref-type="bibr">4</xref>]. The compartmentalization of such B cells in the CNS associates with worse disease outcomes [<xref rid="eji70049-bib-0009" ref-type="bibr">9</xref>] and may explain the limited efficacy of B&#8208;cell depletion therapies in chronic stages of MS [<xref rid="eji70049-bib-0010" ref-type="bibr">10</xref>], as anti&#8208;CD20 monoclonal antibodies cannot reach the CNS.</p><fig position="float" fig-type="FIGURE" id="eji70049-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Reduced frequencies of T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> B cells in the blood of people with progressive MS. (A, B) Representative gating and frequencies of T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> populations within total and memory B cells. (C) Antibody&#8208;secreting cell (ASC) frequencies from in vitro&#8208;cultured memory B cells of treatment&#8208;naive people with relapsing and progressive MS (<italic toggle="yes">n</italic>&#160;=&#160;3&#8211;6). (D) Correlation plot showing the relation between ex vivo CXCR3 expression on memory B cells and in vitro CXCR3 expression on ASCs. (E) ASC frequencies within fresh blood samples from treatment&#8208;naive people with relapsing (<italic toggle="yes">n</italic>&#160;=&#160;25) and progressive (<italic toggle="yes">n</italic>&#160;=&#160;33) MS. All data are presented as mean &#177;SEM and analyzed using Kruskal&#8211;Wallis and Dunn's post hoc tests (A, B), Mann&#8211;Whitney <italic toggle="yes">U</italic>&#8208;tests (A, B, C, E) or Spearman correlation coefficients (D). Outliers were identified and excluded using Grubbs&#8217; test. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01.</p></caption><graphic position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="EJI-55-e70049-g002.jpg"/></fig><p>Taken together, these findings highlight the increase of circulating B cells and CD4<sup>+</sup> T cells as a specific characteristic of MS among CNS AIDs, for which a reduction in circulating T&#8208;bet<sup>+</sup> and CXCR3<sup>+</sup> B cells is associated with progressive disease regardless of age.</p><sec id="eji70049-sec-0020"><title>Author Contributions</title><p>
<bold>Laurens Bogers</bold>: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing &#8211; original draft. <bold>Jasper Rip</bold>: Conceptualization, investigation, methodology, project administration, validation, writing &#8211; review and editing. <bold>Suzanne C. Franken</bold>: Resources, investigation, project administration. <bold>Kirsten L. Kuiper, Ana M. Marques</bold>: Investigation. <bold>Annet F. Wierenga&#8208;Wolf, Marie&#8208;Jos&#233; Melief</bold>: Investigation, methodology. <bold>Cato E.A. Corsten, Romy A.M. Klein Kranenbarg, Janet de Beukelaar, Ide Smets, Beatrijs H. Wokke</bold>: Resources. <bold>Maarten J. Titulaer</bold>: Conceptualization, funding acquisition, resources, project administration. <bold>Joost Smolders</bold>: Conceptualization, funding acquisition, resources, methodology, project administration, supervision, validation, writing &#8211; review and editing. <bold>Marvin M. van Luijn</bold>: Conceptualization, funding acquisition, methodology, project administration, supervision, validation, writing &#8211; review and editing.</p></sec><sec id="eji70049-sec-0040"><title>Ethics Statement</title><p>All donors provided written informed consent. Study protocols were approved by the medical ethics committee of the Erasmus Medical Center (2021&#8208;0251; 2021&#8208;0946; 2019&#8208;0845).</p></sec><sec sec-type="COI-statement" id="eji70049-sec-0050"><title>Conflicts of Interest</title><p>I.S. has received speaker fees from Biogen, Merck, and Sanofi. M.J.T. has filed a patent, on behalf of the Erasmus MC, for methods for typing neurological disorders and cancer, as well as devices for use therein, and has received research funding from EpilepsieNL (NEF 14&#8208;19 &amp; 19&#8208;08), Dioraphte (2001 0403), ZonMw (Memorabel fellowship, VIMP scheme and Open Competition [ACT&#8208;MD]), ItsME, Erasmus MC Foundation, and Erasmus Trustfonds. M.J.T. has served on the scientific advisory board of Horizon Therapeutics/AmGen, ArgenX, and Arialys; for consultation at Guidepoint Global LLC, and at UCB. M.J.T. is co&#8208;PI of the EXTINGUISH trial. M.J.T. has received unrestricted research grants from Euroimmun AG and CSL Behring. M.J.T. has filed a copyright on behalf of ErasmusMC for the PROSE (Patient&#8208;Reported Outcome Scale in Encephalitis). J.S. reports grants for scientific research from Biogen, Hansa Biopharma, Roche, and Siemens Healthineers, and has received speaker and/or consultancy fees from Biogen, Merck, Novartis, Roche, and Sanofi. M.M.v.L. has received research support from EMD Serono, Merck, Novartis, GSK, and Idorsia Pharmaceutical Ltd. The remaining authors declare no conflicts of interest.</p></sec><sec sec-type="peer-review" id="eji70049-sec-0080"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xlink:href="https://publons.com/publon/10.1002/eji.70049" ext-link-type="uri">https://publons.com/publon/10.1002/eji.70049</ext-link>.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="eji70049-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="eji70049-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Supporting file 1</bold>: eji70049&#8208;sup&#8208;0001&#8208;SuppMat.pdf</p></caption><media xlink:href="EJI-55-e70049-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="eji70049-sec-0030"><title>Acknowledgments</title><p>This research is partially funded by Stichting MS Research (19&#8208;1057 MS; 20&#8208;490f MS), Stichting de Merel, Dioraphte (2001 0403), and the Erasmus MC Foundation. We thank Harm de Wit for sorting the cells. We thank all donors for their participation in this study. The graphical abstract and Figure&#160;<xref rid="eji70049-fig-0001" ref-type="fig">1A</xref> were created with <ext-link xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link>.</p></ack><sec sec-type="data-availability" id="eji70049-sec-0070"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="eji70049-bibl-0001"><title>References</title><ref id="eji70049-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="eji70049-cite-0001"><string-name name-style="western"><given-names>J. J.</given-names><surname>Sabatino</surname></string-name>, <string-name name-style="western"><given-names>A.&#8208;K.</given-names><surname>Pr&#246;bstel</surname></string-name>, and <string-name name-style="western"><given-names>S. S.</given-names><surname>Zamvil</surname></string-name>, &#8220;<article-title>B Cells in Autoimmune and Neurodegenerative Central Nervous System Diseases</article-title>,&#8221; <source>Nature Reviews Neuroscience</source><volume>20</volume>, no. <issue>12</issue> (<year>2019 Dec</year>): <fpage>728</fpage>&#8211;<lpage>745</lpage>.<pub-id pub-id-type="pmid">31712781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-019-0233-2</pub-id></mixed-citation></ref><ref id="eji70049-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="eji70049-cite-0002"><string-name name-style="western"><given-names>I.</given-names><surname>Jelcic</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Naghavian</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Fanaswala</surname></string-name>, et&#160;al., &#8220;<article-title>T&#8208;bet+ CXCR3+ B Cells Drive Hyperreactive B&#8208;T Cell Interactions in Multiple Sclerosis</article-title>,&#8221; <source>Cell Reports Medicine</source><volume>6</volume>, no. <issue>3</issue> (<year>2025 Mar</year>): <elocation-id>102027</elocation-id>.<pub-id pub-id-type="pmid">40107244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2025.102027</pub-id><pub-id pub-id-type="pmcid">PMC11970401</pub-id></mixed-citation></ref><ref id="eji70049-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="eji70049-cite-0003"><string-name name-style="western"><given-names>J.</given-names><surname>van Langelaar</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Rijvers</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Janssen</surname></string-name>, et&#160;al., &#8220;<article-title>Induction of Brain&#8208;Infiltrating T&#8208;bet&#8211;Expressing B Cells in Multiple Sclerosis</article-title>,&#8221; <source>Annals of Neurology</source><volume>86</volume>, no. <issue>2</issue> (<year>2019 Aug</year>): <fpage>264</fpage>&#8211;<lpage>278</lpage>.<pub-id pub-id-type="pmid">31136008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25508</pub-id><pub-id pub-id-type="pmcid">PMC6771938</pub-id></mixed-citation></ref><ref id="eji70049-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="eji70049-cite-0004"><string-name name-style="western"><given-names>L.</given-names><surname>Bogers</surname></string-name>, <string-name name-style="western"><given-names>H. J.</given-names><surname>Engelenburg</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Janssen</surname></string-name>, et&#160;al., &#8220;<article-title>Selective Emergence of Antibody&#8208;Secreting Cells in the Multiple Sclerosis Brain</article-title>,&#8221; <source>EBioMedicine</source><volume>89</volume> (<year>2023 Mar</year>): <elocation-id>104465</elocation-id>.<pub-id pub-id-type="pmid">36796230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104465</pub-id><pub-id pub-id-type="pmcid">PMC9958261</pub-id></mixed-citation></ref><ref id="eji70049-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="eji70049-cite-0005"><string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Graner</surname></string-name>, <string-name name-style="western"><given-names>P. G. E.</given-names><surname>Kennedy</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, &#8220;<article-title>The Role of Antibodies in the Pathogenesis of Multiple Sclerosis</article-title>,&#8221; <source>Frontiers in Neurology</source><volume>11</volume> (<year>2020 Oct</year>): <elocation-id>533388</elocation-id>.<pub-id pub-id-type="pmid">33192968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.533388</pub-id><pub-id pub-id-type="pmcid">PMC7606501</pub-id></mixed-citation></ref><ref id="eji70049-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="eji70049-cite-0006"><string-name name-style="western"><given-names>E.</given-names><surname>Lancaster</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Martinez&#8208;Hernandez</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Dalmau</surname></string-name>, &#8220;<article-title>Encephalitis and Antibodies to Synaptic and Neuronal Cell Surface Proteins</article-title>,&#8221; <source>Neurology</source><volume>77</volume>, no. <issue>2</issue> (<year>2011 Jul</year>): <fpage>179</fpage>&#8211;<lpage>189</lpage>.<pub-id pub-id-type="pmid">21747075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318224afde</pub-id><pub-id pub-id-type="pmcid">PMC3140073</pub-id></mixed-citation></ref><ref id="eji70049-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="eji70049-cite-0007"><string-name name-style="western"><given-names>A.</given-names><surname>Uzawa</surname></string-name>, <string-name name-style="western"><given-names>F. C.</given-names><surname>Oertel</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mori</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Paul</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Kuwabara</surname></string-name>, &#8220;<article-title>NMOSD and MOGAD: An Evolving Disease Spectrum</article-title>,&#8221; <source>Nature Reviews Neurology</source><volume>20</volume>, no. <issue>10</issue> (<year>2024 Oct</year>): <fpage>602</fpage>&#8211;<lpage>619</lpage>.<pub-id pub-id-type="pmid">39271964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-01014-1</pub-id></mixed-citation></ref><ref id="eji70049-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="eji70049-cite-0008"><string-name name-style="western"><given-names>F.</given-names><surname>Ingelfinger</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Kuiper</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ulutekin</surname></string-name>, et&#160;al., &#8220;<article-title>Twin Study Dissects CXCR3+ Memory B Cells as Non&#8208;Heritable Feature in Multiple Sclerosis</article-title>,&#8221; <source>Med</source><volume>5</volume>, no. <issue>4</issue> (<year>2024 Apr</year>): <fpage>368</fpage>&#8211;<lpage>373.e3</lpage>.<pub-id pub-id-type="pmid">38531361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medj.2024.02.013</pub-id><pub-id pub-id-type="pmcid">PMC11018360</pub-id></mixed-citation></ref><ref id="eji70049-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="eji70049-cite-0009"><string-name name-style="western"><given-names>N. L.</given-names><surname>Fransen</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>de Jong</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>He&#223;</surname></string-name>, et&#160;al., &#8220;<article-title>Absence of B Cells in Brainstem and White Matter Lesions Associates with Less Severe Disease and Absence of Oligoclonal Bands in MS</article-title>,&#8221; <source>Neurology Neuroimmunology &amp; Neuroinflammation</source><volume>8</volume>, no. <issue>2</issue> (<year>2021 Jan</year>): <elocation-id>e955</elocation-id>.<pub-id pub-id-type="pmid">33504635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/NXI.0000000000000955</pub-id><pub-id pub-id-type="pmcid">PMC7862088</pub-id></mixed-citation></ref><ref id="eji70049-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="eji70049-cite-0010"><string-name name-style="western"><given-names>P.</given-names><surname>Maggi</surname></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Bulcke</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Pedrini</surname></string-name>, et&#160;al., &#8220;<article-title>B Cell Depletion Therapy Does Not Resolve Chronic Active Multiple Sclerosis Lesions</article-title>,&#8221; <source>EBioMedicine</source><volume>94</volume> (<year>2023 Aug</year>): <elocation-id>104701</elocation-id>.<pub-id pub-id-type="pmid">37437310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104701</pub-id><pub-id pub-id-type="pmcid">PMC10436266</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>